Reviews of Selected Pharmacogenetic Tests for Non-Cancer and Cancer Conditions. Technology Assessment

摘要

We assessed four pharmacogenetic tests: (1) cytochrome P450, subfamily IIC, polypeptide 9 (CYP2C9), (2) vitamin K epoxide reductase subunit protein 1 (VKORC1), (3) apolipoprotein E (Apo E), and (4) methylenetetrahydrofolate reductase (MTHFR) for their associations with patients response to therapy with warfarin (CYP2C9 and VKORC1), statins (Apo E), or antifolate chemotherapy (MTHFR). Data Sources: Published studies were identified through an electronic search up to October 2007, and relevant bibliographies were reviewed. Focused searches for specific topics were conducted through April 2008 to identify published randomized controlled trials, systematic reviews, and ongoing clinical trials. We included studies of any design that evaluated adults and abstracted data on all relevant clinical and laboratory outcomes. When sufficient data were available from studies making the same comparisons, the data were summarized in a meta-analysis. Additional subgroup, sensitivity, and meta-regression analyses were conducted as appropriate.